Lindus Health

Lindus (operating as Lindus Health and, on its current website, as Lindus Therapeutics) was founded as a technology-first contract research organization (CRO) that executes clinical trials end-to-end, covering study design, patient recruitment, clinical data capture, monitoring and project management. Its proprietary eClinical platform, Citrus, combines clinical trial management (CTMS), electronic data capture (EDC), telehealth, eConsent and related tooling, and is configured per study; the company also uses AI and automation for study design optimization, central monitoring of study data and biostatistics. Patient enrollment is run through central infrastructure that pairs AI-powered searching of electronic health records with digital pre-screening, digital marketing, clinic and community partnerships, and a patient concierge function.

The company positions itself as an "anti-CRO," contrasting its fixed-fee, milestone-based pricing with the hourly billing model of traditional CROs, and citing trials up to three times faster than conventional providers. It has delivered studies across a wide range of indications, including psychiatry, diagnostics, respiratory health, diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome, insomnia and women's health conditions such as pregnancy, postpartum depression, ovarian cancer and STIs. In October 2024 it packaged its capabilities into an "All-in-One Women's Health CRO" offering.

As of its 2026 website, Lindus has extended beyond services into asset development: it in-licenses phase I-III ready assets in non-ultrarare chronic disease that fit its therapeutic and operational focus, identified using proprietary data and AI models. It targets closing deals on initial assets through 2026 with first trials launching in the first half of 2027, funded from its balance sheet, and is open to exclusive or non-exclusive licenses, territory splits (including ex-APAC), option agreements, joint ventures/SpinCos and co-development, with the intention of developing assets internally before assessing acquisition, partnering, later-stage development or commercialization.

Founding story

Co-founded by Meri Beckwith, Michael Young and Nik Haldimann and launched in 2021. Beckwith, previously a life sciences and healthtech venture investor, says he started the company after being billed hourly by CROs that he felt were indifferent to trial delays, patient problems and data quality, and after his own experience as a participant in Phase III trials where participation was burdensome and unnecessarily paper- and site-based.

Business model

Historically a full-service CRO selling end-to-end clinical trial execution plus site services and its own trial software to life science sponsors, priced as fixed-fee quotes per study with milestone-based payments rather than hourly billing. The company is layering on an asset-development model in which it in-licenses clinical-ready drug assets under various deal structures and advances them through its own trial platform, with downstream value from acquisition, partnering, later-stage development or commercialization.

Fixed-price, per-study quotes with milestone-based payments for CRO, site and technology services; asset in-licensing deals structured around signing, clinical and commercial milestones. Initial in-licensing deals and trial launches are funded from the company's balance sheet.

Traction

Launched in 2021; by January 2025 the company reported 42 end-to-end clinical trials operated and more than 36,000 patients enrolled across North America and Europe, with named engagements including a 7,500-patient device study with Aktiia and a Phase IV insomnia trial with Pharmanovia. A trade report at the same time cited work across 80 clinical trials in the US, UK and Europe and planned studies in menopause, tinnitus, insomnia and childhood myopia. By 2024 it had enrolled over 2,500 patients in women's health trials. Its 2026 site cites 45+ completed phase I-IV trials, a full-time team of over 120, $80M total funding and 82% of trials completing enrollment on or ahead of schedule (measured across 28 trials in the prior three years where Lindus ran enrollment).

Latest developments

The 2026 website sets out an asset-development strategy: in-licensing phase I-III ready assets in non-ultrarare chronic disease, targeting deal closes on initial assets through 2026 and first trials in H1 2027, financed from the balance sheet. Recent additions to the leadership and advisory bench include Sean Sheppard as VP Corporate Development (previously Director of BD and Investments at AtaiBeckley), Gemma Harrison as CPTO leading Citrus R&D, and Dr. Paul Billings joining the Scientific Advisory Board in January 2026. Strategic advisors include Robert Langer, Tim Garnett and Alessandro Falcone.